← board
CDTTW
distress 8/10 · high distress / dilution risk$0.01+97%today0% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
+106%
Price & events
+91.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+97.0%
1D
+18.2%
1W
+97.0%
1M
+97.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
+91.2%
All
Overview
- Market Cap
- $82.04K
- Volume
- 6.83K
- 52 Week Range
- $0.01 – $0.01
- Total Shares
- 6.31M
- Float Shares
- 396.88K
- RVOL
- 26.10x
- Beta
- 1.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-06-03partnershipAZD1656;AZD5658 · Joint development agreement with Manoira Corporation for evaluation in animal health indications.SEC 8-K
- 2025-02-12withdrawalNasdaq determined company had not regained compliance with MVPHS and MVLS requirements, resulting in additional bases for delisting.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.